Bovilis Nasalgen-C RSSAuthorisedThis medicine is authorised for use in the European Unionbovine coronavirus, strain CA25, liveMedicineVeterinaryAuthorised
Page contents OverviewProduct detailsAuthorisation detailsAssessment historyNews on Bovilis Nasalgen-CApplication under evaluationCVMP opinionEuropean Commission decisionOverviewUp-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information websiteProduct details Name of medicine Bovilis Nasalgen-C Active substance bovine coronavirus, strain CA25, live International non-proprietary name (INN) or common name bovine coronavirus, strain CA25, live Pharmacotherapeutic groupImmunologicals for BovidaeLive viral vaccinesbovine coronavirusAuthorisation details EMA product number EMEA/V/C/005906 Assessment historyInitial marketing authorisation documentsCVMP summary of positive opinion for Bovilis Nasalgen-CAdoptedReference Number: EMA/CVMP/42050/2023 English (EN) (127.29 KB - PDF)First published: 17/02/2023ViewNews on Bovilis Nasalgen-CMeeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 8-10 October 202411/10/2024Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 5-7 December 202308/12/2023Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 14-16 February 202317/02/2023This page was last updated on 03/04/2024Share this page